TABLE 1.

Baseline characteristics, prior therapy and disease burden

Patient	Sex	Age, years	Weight, kg	BMI, kg/m2	Race	Histologic subtype	Surgical excisiona	Systemic therapya	Target lesion sitesb	Non- target lesion sitesb	Vemurafenib dose, mg BID
1	Male	17	52.4	17.3	White	Nodular	Yes	None	Liver, lymph node	Lung, skin	720
2	Male	15	138.5	40.0	White	Nodular	Yes	IFN	Lung	Lung, sacrum	720
3	Male	16	64.7	19.7	White	Superficial spreading	Yes	None	Lymph node	Lymph node	720
4	Female	16	59.5	21.9	White	NA	Yes	TMZ	Brain	Brain	960
5	Female	15	86.4	34.1	Black or AA	NA	No	None	Skin, lymph node, soft tissue	Soft tissue	960
6	Male	16	49.2	18.3	White	Superficial spreading	Yes	None	Liver	Bone, lung, liver	960

AA, African-American; BID, twice daily; IFN, interferon; NA, not available; TMZ, temozolomide.

^aPrior to study entry.

^bAt study entry.